Estabrook Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.26M Buy
329,763
+52,428
+19% +$1.4M 1.35% 21
2025
Q4
$6.91M Sell
277,335
-26,115
-9% -$659K 1.01% 28
2025
Q3
$7.73M Sell
303,450
-15,475
-5% -$382K 1.13% 27
2025
Q2
$7.73M Buy
318,925
+17,615
+6% +$411K 1.19% 24
2025
Q1
$7.64M Buy
301,310
+5,280
+2% +$138K 1.23% 23
2024
Q4
$7.85M Sell
296,030
-64,456
-18% -$1.75M 1.21% 22
2024
Q3
$10.4M Sell
360,486
-540
-0.1% -$15.8K 1.56% 17
2024
Q2
$10.1M Buy
361,026
+1,148
+0.3% +$31.6K 1.55% 16
2024
Q1
$9.99M Buy
359,878
+44,806
+14% +$1.24M 1.54% 18
2023
Q4
$9.07M Sell
315,072
-18,145
-5% -$549K 1.48% 19
2023
Q3
$11.1M Buy
333,217
+26,208
+9% +$927K 1.95% 12
2023
Q2
$11.3M Sell
307,009
-593
-0.2% -$23.1K 1.88% 12
2023
Q1
$12.6M Sell
307,602
-821
-0.3% -$35.5K 2.18% 10
2022
Q4
$15.8M Buy
308,423
+3,273
+1% +$157K 2.72% 8
2022
Q3
$13.4M Buy
305,150
+2,893
+1% +$141K 2.48% 10
2022
Q2
$15.8M Sell
302,257
-1,690
-0.6% -$86.1K 2.72% 7
2022
Q1
$15.7M Buy
303,947
+190
+0.1% +$9.86K 2.31% 9
2021
Q4
$17.9M Sell
303,757
-7,807
-3% -$387K 2.54% 7
2021
Q3
$13.4M Sell
311,564
-9,359
-3% -$415K 2.11% 14
2021
Q2
$12.6M Sell
320,923
-12,665
-4% -$493K 1.91% 15
2021
Q1
$12.1M Sell
333,588
-558
-0.2% -$19.8K 1.86% 16
2020
Q4
$12.3M Sell
334,146
-18,452
-5% -$677K 2.04% 13
2020
Q3
$12.3M Sell
352,598
-6,463
-2% -$227K 2.25% 11
2020
Q2
$11.1M Sell
359,061
-5,254
-1% -$178K 2.12% 12
2020
Q1
$11.3M Sell
364,315
-13,953
-4% -$475K 2.37% 12
2019
Q4
$14.1M Buy
378,268
+17,017
+5% +$606K 2.11% 15
2019
Q3
$12.3M Sell
361,251
-1,107
-0.3% -$40.3K 2.05% 14
2019
Q2
$14.9M Sell
362,358
-6,042
-2% -$240K 2.44% 13
2019
Q1
$14.8M Sell
368,400
-2,352
-0.6% -$94.2K 2.46% 12
2018
Q4
$15.4M Sell
370,752
-8,938
-2% -$371K 2.85% 7
2018
Q3
$15.9M Sell
379,690
-27,324
-7% -$1.05M 2.4% 14
2018
Q2
$14M Sell
407,014
-21,149
-5% -$723K 2.21% 16
2018
Q1
$14.4M Sell
428,163
-3,532
-0.8% -$121K 2.26% 13
2017
Q4
$14.8M Sell
431,695
-6,434
-1% -$219K 2.24% 14
2017
Q3
$14.8M Buy
438,129
+526
+0.1% +$16.9K 2.31% 13
2017
Q2
$13.9M Buy
437,603
+5,081
+1% +$160K 2.22% 14
2017
Q1
$14M Sell
432,522
-10,248
-2% -$323K 2.2% 15
2016
Q4
$13.6M Sell
442,770
-39,789
-8% -$1.21M 2.14% 15
2016
Q3
$15.5M Sell
482,559
-7,829
-2% -$262K 2.28% 13
2016
Q2
$16.4M Sell
490,388
-24,669
-5% -$787K 2.45% 12
2016
Q1
$14.5M Sell
515,057
-6,252
-1% -$179K 2.14% 16
2015
Q4
$16M Sell
521,309
-9,469
-2% -$298K 2.31% 15
2015
Q3
$15.8M Sell
530,778
-13,055
-2% -$419K 2.28% 18
2015
Q2
$17.3M Sell
543,833
-21,431
-4% -$698K 2.14% 21
2015
Q1
$18.7M Sell
565,264
-27,988
-5% -$890K 2.18% 17
2014
Q4
$17.5M Sell
593,252
-8,012
-1% -$230K 1.93% 21
2014
Q3
$16.9M Buy
601,264
+10,965
+2% +$308K 1.81% 24
2014
Q2
$16.6M Buy
590,299
+88,804
+18% +$2.53M 1.71% 28
2014
Q1
$15.3M Sell
501,495
-13,958
-3% -$416K 1.56% 30
2013
Q4
$15M Buy
515,453
+2,666
+0.5% +$77.6K 1.54% 27
2013
Q3
$14M Sell
512,787
-11,594
-2% -$315K 1.53% 27
2013
Q2
$13.9M Buy
+524,381
New +$14.5M 1.48% 29

Other funds holding PFE

Estabrook Capital Management's PFE Position: Q1 2026 in Review

Estabrook Capital Management increased its Pfizer (PFE) stake by 19% in Q1 2026, buying an estimated $1.4M and bringing the position to 329,763 shares worth $9.26M. The position accounts for 1.35% of the portfolio, ranked #21.

Estabrook Capital Management first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $18.7M in Q1 2015. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Estabrook Capital Management held 329,763 shares of Pfizer worth $9.26M as of Q1 2026.
  • Estabrook Capital Management bought 52,428 Pfizer shares in Q1 2026, an estimated $1.4M.
  • Pfizer made up 1.35% of Estabrook Capital Management's portfolio in Q1 2026, its #21 holding.
  • Estabrook Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Estabrook Capital Management's Pfizer position peaked at $18.7M in Q1 2015.
  • 2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Estabrook Capital Management's 13F filing for Q1 2026, filed 14 May 2026.